Taipei, Taiwan, October 5, 2026
AnnJi Pharmaceutical Co., Ltd. has announced that it is advancing AJ201 (rosolutamide) into the pivotal Phase 3 ROMA-KD clinical trial for spinal and bulbar muscular atrophy (SBMA), also known as Kennedy’s disease. The company plans to proceed with U.S. site activation following submission of the Phase 3 protocol to the U.S. Food and Drug Administration under its active Investigational New Drug (IND) application. AJ201 is an investigational oral small molecule being developed as a potential disease-modifying treatment for SBMA, a rare inherited neuromuscular disorder for which there is currently no FDA-approved therapy. The program has received FDA Fast Track Designation and Orphan Drug Designation in both the United States and European Union.
AJ201 Advances Toward Pivotal Phase 3 Development
The global ROMA-KD Phase 3 trial is designed as a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AJ201 in ambulatory individuals with symptomatic SBMA. AnnJi expects approximately 200 patients to enroll globally, with the United States serving as an important region for the clinical program. The study is intended to generate data that could support potential regulatory submissions in multiple markets. The company said its Phase 3 strategy builds on encouraging findings from the completed Phase 2 study of AJ201, announced in May 2025, as well as subsequent discussions with regulatory authorities. AJ201 is being developed as a potential first-in-class therapeutic approach for SBMA. The investigational oral small molecule is designed to address multiple biological mechanisms associated with the disease rather than focusing on a single pathway. According to AnnJi, AJ201 promotes the clearance of the pathogenic mutant androgen receptor (mAR) protein while also activating cellular stress-response pathways, including Nrf1, Nrf2 and HSF1. These mechanisms are being investigated for their potential to address protein toxicity, oxidative stress and other cellular processes involved in SBMA progression.
Novel Approach Targets SBMA Disease Mechanisms
Spinal and bulbar muscular atrophy, or Kennedy’s disease, is a rare X-linked inherited neuromuscular disorder caused by a CAG repeat expansion in the androgen receptor gene. The resulting mutant androgen receptor protein contributes to degeneration of motor neurons and muscle through several disease mechanisms, including cellular toxicity, oxidative stress and neuroinflammation. Patients can experience progressive muscle weakness and difficulties affecting activities such as walking, swallowing and speaking. There is currently no FDA-approved treatment specifically for SBMA, creating a significant unmet medical need for patients and families affected by the disorder. AnnJi is pursuing AJ201 as a potential disease-modifying therapy designed to target several biological mechanisms involved in the disease. The company believes this multi-mechanism approach could potentially address aspects of SBMA pathology associated with mutant protein accumulation and cellular stress responses. However, AJ201 remains investigational and has not been approved by any regulatory authority. The program has received important regulatory designations that support its development. FDA Fast Track Designation is intended to facilitate development and regulatory review of therapies addressing serious conditions with unmet medical needs, while Orphan Drug Designation recognizes treatments being developed for rare diseases. AJ201 has received Orphan Drug Designation from both the U.S. FDA and the European Union.
Advertisement
AnnJi Strengthens Patient-Centered SBMA Development
Alongside its clinical development program, AnnJi has established an SBMA Patient and Care Partner Advisory Council to incorporate perspectives from people living with the disease and their care partners. The council provides a structured forum for ongoing dialogue between AnnJi and the SBMA community, with patient perspectives potentially informing areas such as clinical-study design and patient-facing communications. The company said the advisory council operates independently of its clinical trials, and participation does not affect trial eligibility or enrollment. AnnJi plans to coordinate global site activation and patient enrollment as it progresses the ROMA-KD program in line with its broader development strategy.
The advancement of AJ201 into pivotal Phase 3 development represents an important milestone in the search for new treatment options for SBMA/Kennedy’s disease. The upcoming ROMA-KD trial will be critical in determining whether the investigational therapy can demonstrate sufficient efficacy and safety to support future regulatory submissions. As the program moves forward, clinical results from the Phase 3 study will help establish the potential role of AJ201 in addressing the substantial unmet needs of the SBMA community.
Source: AnnJi Pharmaceutical press release
